Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. (Q51838813)

From Wikidata

Jump to navigation Jump to search

scientific article published on 4 February 2009

Language	Label	Description	Also known as
English	Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.	scientific article published on 4 February 2009

Statements

scholarly article

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer. (English)

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

Claudio Jeldres

5

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

7

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

Giorgio Guazzoni

10

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

Alberto Briganti

6

object named as

Alberto Briganti

1 reference

Europe PubMed Central

13 April 2018

Pierre I Karakiewicz

2

object named as

Pierre I Karakiewicz

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

4

object named as

Paul Perrotte

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

Francesco Montorsi

12

object named as

Francesco Montorsi

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

11

object named as

Andrea Salonia

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

Nazareno Suardi

8

object named as

Nazareno Suardi

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

Umberto Capitanio

1

object named as

Umberto Capitanio

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

9

object named as

Andrea Cestari

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

author name string

Luc Valiquette

3

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

language of work or name

0 references

publication date

4 February 2009

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

73

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

5

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

1087-1091

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic Value of Tumour Ploidy and Comorbidity

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

EAU guidelines on prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Initial extended transrectal prostate biopsy--are more prostate cancers detected with 18 cores than with 12 cores?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Words of wisdom. Re: Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Model selection and model averaging in phylogenetics: advantages of akaike information criterion and bayesian approaches over likelihood ratio tests

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Validation of the Contemporary Epstein Criteria for Insignificant Prostate Cancer in European Men

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Assessment of Biochemical Recurrence Rate in Patients With Pathologically Confirmed Insignificant Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Open to debate. The motion: at least 18 cores are necessary to make a prostatic biopsy useful

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Editorial comment on: systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Improving model robustness with bootstrapping -- application to optimal discriminant analysis for ordinal responses (ODAO)

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2008.10.048

7 January 2021

Identifiers

10.1016/J.UROLOGY.2008.10.048

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

1 reference

Europe PubMed Central

13 April 2018

http://europepmc.org/abstract/MED/19195695

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51838813&oldid=1739652507"